(NASDAQ: SMMT) Summit Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.63%.
Summit Therapeutics's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast SMMT's revenue for 2026 to be $26,231,030,553, with the lowest SMMT revenue forecast at $8,111,929,606, and the highest SMMT revenue forecast at $44,350,131,500. On average, 3 Wall Street analysts forecast SMMT's revenue for 2027 to be $134,635,908,015, with the lowest SMMT revenue forecast at $72,859,876,825, and the highest SMMT revenue forecast at $168,809,255,101.
In 2028, SMMT is forecast to generate $985,061,109,982 in revenue, with the lowest revenue forecast at $645,562,107,008 and the highest revenue forecast at $1,560,373,906,603.